Jazz PharmaceuticalsMEX:JAZZN 73 EBITDA Margin % is 48.69% as of Mar. 2026, which is 48% above its 10-year median of 32.81. GuruFocus rates MEX:JAZZN with a GF Score™ of 73/100 and a GF Value™ of MXN1,641.59. The stock has 6 warning signs investors should review. Among 945 Biotechnology companies, Jazz Pharmaceuticals ranks better than 78.94% on this metric.
Jazz Pharmaceuticals (MEX:JAZZN) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Jazz Pharmaceuticals EBITDA Margin % Related Terms
Jazz Pharmaceuticals EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Jazz Pharmaceuticals's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:JAZZN vs ASND, SMMT, BBIO: EBITDA Margin % Comparison
For the Biotechnology subindustry, Jazz Pharmaceuticals's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jazz Pharmaceuticals EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Jazz Pharmaceuticals's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Jazz Pharmaceuticals's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jazz Pharmaceuticals (MEX:JAZZN) has a EBITDA Margin % of 48.69% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Jazz Pharmaceuticals and its competitors. This is 48% above median its historical median of 32.81. Over the past decade, Jazz Pharmaceuticals' EBITDA Margin % has ranged from 6.17 to 47.59. According to the industry distribution chart, Jazz Pharmaceuticals ranks #199 out of 945 companies in the Biotechnology industry, placing it in the top 21.1%.
Is Jazz Pharmaceuticals' EBITDA Margin % too high?
Jazz Pharmaceuticals' current EBITDA Margin % of 48.69% is 48% above median its 10-year median of 32.81. Over the past 10 years, this metric has ranged from a low of 6.17 to a high of 47.59. Based on the distribution chart, Jazz Pharmaceuticals ranks #199 out of 945 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Jazz Pharmaceuticals has a GF Score™ of 73/100, reflecting its overall financial health beyond just this single metric.
How does Jazz Pharmaceuticals' EBITDA Margin % compare to ASND and SMMT?
According to the Biotechnology industry distribution chart, Jazz Pharmaceuticals ranks #199 out of 945 companies for EBITDA Margin %. This places Jazz Pharmaceuticals in the top 21% of its industry — outperforming the majority of peers. Historically, Jazz Pharmaceuticals' own EBITDA Margin % has ranged from 6.17 to 47.59 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Jazz Pharmaceuticals and its competitors. Jazz Pharmaceuticals's current EBITDA Margin % is 48.69%, which is 48% above median its own 10-year median of 32.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jazz Pharmaceuticals stock overvalued right now?
Jazz Pharmaceuticals (MEX:JAZZN) has a current EBITDA Margin % of 48.69%. The stock's GF Value™ is MXN1,641.59, compared to a current price of MXN2,500.00 — trading 52.3% above its estimated fair value. The current EBITDA Margin % is 48.69%, which is 48% above median its 10-year median of 32.81. Jazz Pharmaceuticals' overall GF Score™ is 73/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Jazz Pharmaceuticals (MEX:JAZZN), the current EBITDA Margin % is 48.69% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jazz Pharmaceuticals (MEX:JAZZN) Overvalued in 2026?
Based on GuruFocus' analysis, Jazz Pharmaceuticals stock appears to be overvalued.
The current stock price of MXN2,500.00 is trading 52.3% above its estimated GF Value™ of MXN1,641.59.
Key valuation signals for MEX:JAZZN:
EBITDA Margin %: 48.69% (48% above median its 10-year median of 32.81)
GF Value™: MXN1,641.59 vs. price of MXN2,500.00 (52.3% above fair value)
No single metric tells the full story. See the MEX:JAZZN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
73GF Score
Get the complete analysis for MEX:JAZZN
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:JAZZN has been successfully added to your 
